Fundz

Protego Biopharma raises $130M in a series B funding round led by Novartis Venture Fund and Forbion to advance its AL amyloidosis therapy into pivotal trials.

PRIVATEDec 01, 2025

Amount Raised

$130 Million

Round Type

Series B

San DiegoBiotechnology

Investors

MPM BioImpactOmega FundsDroia VenturesYK BioventuresDigitalis VenturesVida VenturesLightspeed Venture PartnersScripps ResearchNovartis Venture FundForbion

Description

Protego Biopharma has secured $130 million in an oversubscribed series B funding round to advance its lead candidate, PROT-001, into pivotal trials. The round was led by Novartis Venture Fund and Forbion, with support from several new and existing investors. The funding will help Protego progress towards delivering a potential first disease-modifying therapy for AL amyloidosis. This marks a significant step in addressing a rare, life-threatening condition.

Quick answer

Protego Biopharma raised $130 Million in a Series B round, dated December 1, 2025. Investors: MPM BioImpact, Omega Funds, Droia Ventures, YK Bioventures, Digitalis Ventures, Vida Ventures, Lightspeed Venture Partners and Scripps Research. Protego Biopharma is based in San Diego, California, United States.

How much did Protego Biopharma raise?
Protego Biopharma raised $130 Million in a Series B round on December 1, 2025.
Who invested in Protego Biopharma?
MPM BioImpact, Omega Funds, Droia Ventures, YK Bioventures, Digitalis Ventures, Vida Ventures, Lightspeed Venture Partners and Scripps Research are named as investors in this round.
What does Protego Biopharma do?
Protego Bio is a clinical-stage company focused on the discovery and development of first-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases.
Where is Protego Biopharma based and how big is it?
Protego Biopharma is based in San Diego, California, United States. Fundz records about 26 employees.
Who are the decision-makers at Protego Biopharma?
Fundz holds 3 contacts at Protego Biopharma, including the Chief Science Officer. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Protego Biopharma that raised within 45 days of this round, from Fundz verified event records.

  • CRB raised $50M on January 15, 2026.
  • Transition Metal Solutions raised $6M (Seed) on January 15, 2026.
  • SenseUP raised $3.5M (Seed) on January 15, 2026.
  • Cantai Therapeutics raised $3M (Seed) on January 15, 2026.
  • Science&Humans raised $7.9M (Series A) on January 15, 2026.
  • MARS Bioimaging raised $15M (Series A) on January 14, 2026.

Who to call at Protego Biopharma, and when

A new round usually means Protego Biopharma is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Protego Biopharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Protego Biopharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Protego Biopharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Protego Biopharma

Location

San Diego, California, United States

About

Protego Bio is a clinical-stage company focused on the discovery and development of first-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases. We are exploring monogenetic protein misfolding diseases that cause myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases. Our approach builds on the proven pharmacological chaperone strategy exemplified by tafamidis, which was discovered and developed by our cofounders, Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, for the treatment of transthyretin amyloidosis.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Protego Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

3 contacts
Verified contactsMike P., Chief Science Officer hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Protego Biopharma's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Protego Biopharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.